This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1–2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events.
"synopsis" may belong to another edition of this title.
Seller: Ria Christie Collections, Uxbridge, United Kingdom
Condition: New. In. Seller Inventory # ria9781858734385_new
Quantity: Over 20 available
Seller: THE SAINT BOOKSTORE, Southport, United Kingdom
Paperback / softback. Condition: New. This item is printed on demand. New copy - Usually dispatched within 5-9 working days 98. Seller Inventory # C9781858734385
Quantity: Over 20 available
Seller: BuchWeltWeit Ludwig Meier e.K., Bergisch Gladbach, Germany
Taschenbuch. Condition: Neu. This item is printed on demand - it takes 3-4 days longer - Neuware -This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1-2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events. 56 pp. Englisch. Seller Inventory # 9781858734385
Quantity: 2 available
Seller: AHA-BUCH GmbH, Einbeck, Germany
Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware - Printed after ordering - This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. Atrial fibrillation (AF) affects an estimated 1-2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events. Seller Inventory # 9781858734385
Quantity: 1 available
Seller: moluna, Greven, Germany
Condition: New. Seller Inventory # 4290752
Quantity: Over 20 available
Seller: Revaluation Books, Exeter, United Kingdom
Paperback. Condition: Brand New. revised edition. 47 pages. 8.00x5.00x0.25 inches. In Stock. Seller Inventory # x-185873438X
Quantity: 2 available
Seller: Majestic Books, Hounslow, United Kingdom
Condition: New. Print on Demand pp. 56. Seller Inventory # 356224488
Quantity: 4 available
Seller: Books Puddle, New York, NY, U.S.A.
Condition: New. pp. 56. Seller Inventory # 26357315127
Quantity: 4 available
Seller: Biblios, Frankfurt am main, HESSE, Germany
Condition: New. PRINT ON DEMAND pp. 56. Seller Inventory # 18357315133
Quantity: 4 available
Seller: buchversandmimpf2000, Emtmannsberg, BAYE, Germany
Taschenbuch. Condition: Neu. Neuware -This handbook offers timely investigation of current pharmaceutical trends, clinical guidelines, novel treatments, and ongoing pipeline developments, including ground-breaking advances in the use of novel oral anticoagulants. ¿Atrial fibrillation (AF) affects an estimated 1¿2% of the population and is the most common cause of sustained cardiac arrhythmia. Critically, the number of patients developing AF is expected to double in the next five decades, leading to increased incidence of stroke, heart failure and other serious thromboembolic events.Springer-Verlag GmbH, Tiergartenstr. 17, 69121 Heidelberg 56 pp. Englisch. Seller Inventory # 9781858734385
Quantity: 2 available